TELA News and Press, TELA Bio Inc. From 08/16/22

Tela Bio ( NASDAQ: TELA ) priced an offering of 4M common shares at $8 apiece to raise $32M in gross proceeds. The company granted the underwriter a 30-day option to buy up to an additional 600K shares. Tela intends to use the net proceeds for working capital a...

TELA Bio ( NASDAQ: TELA ) on Monday announced an underwritten public offering of shares . TELA expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares to be sold in the proposed offering at the public offering price. There can be n...

Image source: The Motley Fool. TELA Bio, Inc. (NASDAQ: TELA) Q2 2022 Earnings Call Aug 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: TELA Bio, Inc. (TELA) Q2 2022 Earnings Call Transcript

TELA Bio press release ( NASDAQ: TELA ): Q2 GAAP EPS of -$0.88 (vs. -$0.57 Y/Y). Revenue of $10.4M (+37.6% Y/Y). FY22 revenue expected to be in the range from $42M to $45M (vs. consensus of $42.27M) For further details see: TELA Bio Q2 GAAP EPS of -$0.88, rev...

MALVERN, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's o...

24-Month BRAVO study results showed a 2.6% recurrence rate in diverse clinical scenarios Robotic Reinforced Biologic Augmented Repair (ReBAR) study showed a 1.9% recurrence rate at two-year mark MALVERN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDA...

MALVERN, Pa., July 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own a...

MALVERN, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the p...

TELA Bio (NASDAQ:TELA) stated Monday that it has secured up to $50M credit facility with MidCap Financial, a portion of which is used to fully repay the existing $30M credit facility with OrbiMed Royalty Opportunities II, LP. The facility bears interest at a rate equal to 6.25% plus the ...

MALVERN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the p...